NCT02172911: A trial that was reported late by Inovio Pharmaceuticals
This trial has reported, although it was 85 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02172911 |
|---|---|
| Title | Phase I/IIA, Open-Label, Safety, Tolerability, and Immunogenicity Study of INO-3112 Delivered by Electroporation (EP) in Women With Cervical Cancer After Chemoradiation for Newly Diagnosed Disease or Therapy for Recurrent and/or Persistent Disease |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 6, 2014 |
| Completion date | Sept. 7, 2017 |
| Required reporting date | Sept. 7, 2020, midnight |
| Actual reporting date | Dec. 1, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 85 |